drugset / Trial / NCT01920555

Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

NCT01920555

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is looking at the efficacy, durability, safety, and tolerability of multiple single doses of Ketamine vs. active placebo for treating patients with treatment resistant depression who are taking an antidepressant that is not working for them.

Timeline

Start
2014-12
Primary completion
2017-01
Completion
2017-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ketamine Small molecule 0.1 mg/kg Intravenous
Comparator Ketamine Small molecule 0.2 mg/kg Intravenous
Comparator Ketamine Small molecule 0.5 mg/kg Intravenous
Comparator Ketamine Small molecule 1 mg/kg Intravenous

Indications

No indication recorded.